ArticleSAGE open medicine2017
Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines.
Article in SAGE open medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Drug interaction potential of Ankaferd blood stopper® in human hepatocarcinoma cells.Turkish journal of medical sciences · 2023Article
- Environmental toxicants and health adversities: A review on interventions of phytochemicals.Journal of public health research · 2023Article
- Antimicrobial activities of Ankaferd BloodStopper, hypochlorous acid, and chlorhexidine against specific organisms.Turkish journal of medical sciences · 2022Article
- Antineoplastic Effects of Ankaferd Hemostat.BioMed research international · 2022Review
- The effect of Ankaferd blood stopper on liver damage in experimental obstructive jaundiceTurkish journal of medical sciences · 2021Article
- Ankaferd hemostat: from molecules to medicineTurkish journal of medical sciences · 2020Review
- Histopathological and mechanical effects of Ankaferd Blood Stopper® on wound healing in rats: an experimental modelTurkish journal of medical sciences · 2020Article
- Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper).SAGE open medicine · 2020Review
- Beneficial Role of Phytochemicals on Oxidative Stress and Age-Related Diseases.BioMed research international · 2019Review
- Analysis of the Antiproliferative Effect of Ankaferd Hemostat on Caco-2 Colon Cancer Cells via LC/MS Shotgun Proteomics Approach.BioMed research international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAnkaferd hemostat is the first topical hemostatic agent about the red blood cell-fibrinogen relations tested in the clinical trials. Ankaferd hemostat consists of standardized plant extracts including
methodsDissimilar melanoma cell lines and primary cells were used in this study. These cells were treated with different concentrations of Ankaferd hemostat to assess the impact of different dosages of the drug. All cells treated with different concentrations were incubated for different time intervals. After the data had been obtained, one-tailed T-test was used to determine whether the Ankaferd hemostat would have any significant inhibitory impact on cell growth.
resultsWe demonstrated in this study that cells treated with Ankaferd hemostat showed a significant decrease in cell viability compared to control groups. The cells showed different resistances against Ankaferd hemostat which depended on the dosage applied and the time treated cells had been incubated. We also demonstrated an inverse relationship between the concentration of the drug and the incubation time on one hand and the viability of the cells on the other hand, that is, increasing the concentration of the drug and the incubation time had a negative impact on cell viability.
conclusionThe findings in our study contribute to our knowledge about the anticancer impact of Ankaferd hemostat on different melanoma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.